Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Benralizumab in patients with refractory eosinophilic cystitis to improves symptoms and reduces bladder eosinophils

Next Previous
Trial Profile

Efficacy of Benralizumab in patients with refractory eosinophilic cystitis to improves symptoms and reduces bladder eosinophils

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Bladder disorders; Cystitis; Eosinophilia
  • Focus Therapeutic Use

Most Recent Events

  • 22 Apr 2021 New trial record
  • 01 Mar 2021 Results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top